Trial Profile
A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Haemorrhagic cystitis
- Focus Therapeutic Use
- Sponsors Lipella Pharmaceuticals
- 21 Sep 2023 According to a Lipella Pharmaceuticals media release, results from this trial have been the published in the peer-reviewed Journal of Urology and Nephrology.
- 21 Sep 2023 Results published in the Lipella Pharmaceuticals Media Release.
- 06 Jun 2023 Results assessing the safety, tolerability, pharmacokinetics and efficacy of LP-10 in subjects with refractory moderate to severe hemorrhagic cystitis, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.